1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
NLS Pharmaceutics AG

NLS Pharmaceutics AG

NLSPW
NLS Pharmaceutics AGUS flagNASDAQ Capital Market
0.02
USD
+0.02
- -
7,432.00Market Cap
NLS Pharmaceutics AG
NLSPW
(NASDAQ Capital Market)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
1
2
1
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-6,311.67
-4,823.53
-1,500.1
-1,137.35
-3,046.35
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
1
1
1
1
1
- -
1
2
2
2
2
2
Depreciation Expense
-13
-15
-17
-20
-21
-24
-25
-22
-26
-23
-12
-27
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-5,255.83
-4,703.1
-1,659.92
-1,172.81
-3,132.75
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-3
-8
3
5
-15
-11
13
-3
-7
-30
Working Capital
- -
- -
- -
2
- -
- -
2
1
- -
2
1
- -
LT Debt
- -
2
-1
-9
4
7
-12
-8
15
- -
-4
-29
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-109.14%
-258.11%
568.49%
Free Cash Flow
-3.92%
-25.35%
-75.01%
Net Income, GAAP
12.12%
13.6%
121.1%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Apollomics, Inc. (APLM)
Lyka Labs Limited (LYKALABS.BO)
PolarityTE, Inc. (PTE)
Senti Biosciences, Inc. (SNTI)
Taysha Gene Therapies, Inc. (TSHA)
Suzhou Ribo Life Science Co (6938.HK)
Business
NLS Pharmaceutics Ltd. (Nasdaq: NLSP; NLSPW), formerly NLS Pharmaceutics AG, operates as a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for rare and complex central nervous system (CNS) disorders, including narcolepsy, idiopathic hypersomnia, attention deficit hyperactivity disorder (ADHD) and other neurological conditions. The company offers a pipeline of product candidates comprising Quilience, a modified-release formulation of mazindol for treating excessive daytime sleepiness and cataplexy associated with narcolepsy; Nolazol, a next-generation prodrug of methylphenidate for ADHD; DOXA, a first-in-class dual orexin receptor agonist platform for sleep-wake disorders; and early-stage assets such as NLS-4 (lauflumide, a wake-promoting agent for chronic fatigue including long-COVID symptoms), NLS-3 (reverse ester of methylphenidate), NLS-8 (melatonin ML1A receptor agonist), NLS-11 (norepinephrine/dopamine reuptake inhibitor with muscarinic antagonism) and NLS-12 (similar reuptake inhibitor targeting muscarinic M4 receptors). Founded in 2015 and headquartered in Zurich, Switzerland, NLS Pharmaceutics targets patient populations with unmet needs in neurobehavioral and neurocognitive disorders across global markets, primarily through clinical trials in the United States and Europe. In recent developments, the company completed a merger with Kadimastem Ltd. in October 2025, creating NewcelX with an expanded pipeline incorporating Kadimastem's allogeneic cell therapies AstroRx for amyotrophic lateral sclerosis (ALS) and IsletRx for Type 1 diabetes; announced a 1-for-10 reverse share split and name change to NLS Pharmaceutics Ltd. in October 2025; received shareholder approvals for the Kadimastem merger in September 2025; and entered a definitive merger agreement in November 2024 originally targeting a January 2025 close.